Management of hyperlipidemias: An update

Indian Journal of Dermatology, Venereology and Leprology

Volumn 75, Issue 5, 2009, Pages 452-462

  Ranjan, Nitin ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Guidelines; Lipid metabolism; Low density lipoprotein cholesterol; Statins

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; APOLIPOPROTEIN C; ATORVASTATIN; BILE ACID; CHOLESTEROL; CHYLOMICRON; CLOFIBRATE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; GUGGULSTERONE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SQUALENE SYNTHASE; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

BIOSYNTHESIS; CATABOLISM; CHOLESTEROL BLOOD LEVEL; DIET; DISEASE MARKER; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG TARGETING; EXERCISE; FOOD INTAKE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INTESTINE; LIFESTYLE MODIFICATION; LIPID METABOLISM; LIPID TRANSPORT; LIPOPROTEIN BLOOD LEVEL; LIVER; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; SMOKING; SMOKING CESSATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT CONTROL; XANTHELASMA; XANTHOMA;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; DISEASE MANAGEMENT; HUMANS; HYPERLIPIDEMIAS; LIPID METABOLISM;

EID: 70349421032     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: 10.4103/0378-6323.55387     Document Type: Review

References (74)

1. Olofsson S-O, Stillemark-Billton P, Asp L. Intracellular assembly of VLDL. Two major steps in separate cell compartments. Trends Cardiovasc Med 2000;10:338-345
2. Cooper AD. Hepatic uptake of chylomicron remnants. J Lipid Res 1997;38:2173-2192
3. Barter PJ, Brewer HB, Chapman MJ, Hennekans CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:160-167
4. Attie AD, Kastelein JP and Hayden MR. Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. J Lipid Res 2001;42,1717-1726
5. Krieger M. Scavenger receptor class B type 1 is a multiligand HDL receptor that influences diverse physiologic systems. J Clin Invest 2001;108:793-797
6. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins - an integrated approach to mechanisms and disorders. N Engl J Med 1967;276:34-44.
7. Havel RJ. Classification of the hyperlipidemias. Annu Rev Med 1977;28:195-209.
8. Havel RJ, Goldstein JL, Brown MS. Lipoproteins and lipid transport. In: Bondy PK, Rosenberg LE, eds. Metabolic control and disease. Philadelphia: Saunders,1980:446.
9. Seymour CA. Xanthomas and abnormalities of lipid metabolism and storage. In: Burns T, Breathnach S, Cox N, Griffiths C, editors, Rook's textbook of dermatology. Oxford: Blackwell Publishing; 2004. p. 57.60 - 57.77.
10. Odom RB, James WD, Berger TG. Errors in in metabolism. In: Andrew's disease of the skin, 9th ed. Philadelphia: W.B Saunders, 2000:648-671
11. Bergman R. The pathogenesis and clinical significance of xanthelasma palpebrarum. J Am Acad Dermatol 1994;30:236-242
12. Bergman R, Kasif Y, Aviram M, et al. Normolipidemic xanthelasma plapebrarum: lipid composition, cholesterol metabolism in monocyte-derived macrophages, and plasma lipid peroxidation. Acta Dermato-Venereol (Stockh) 1996;76:107-110
13. Vermeer BJ, Mateysen AAE, van Gent CM, et al. The lipid composition and localization of free and esterified cholesterol in different types of xanthomas. J Invest Dermatol 1982; 78:305-308
14. Ribera M, Pinto X, Argimon M, et al. Lipid metabolism and apolipoprotein E phenotypes in patients with xanthelasma. Am J Med 1995;99:485-490.
15. Bergman R. Xanthelasma palpebrarum and risk of atherosclerosis. Int J Dermatol 1998;37:343-345
16. George WM. Cutaneous findings related to cardiovascular disorders. Int J Dermatol. 1998;37:161-172
17. Eedy DJ. Treatment of xanthelasma by excision with secondary intention healing. Clin Exp Dermatol 1996;21:273-275
18. 2 laser for the treatment of xanthelasma palpebrarum. Ann Plast Surg 1993;31:504-507
19. Schönermark MP, Raulin C. Treatment of xanthelasma palpebrarum with the pulsed dye laser. Lasers Surg Med 1996;19:336-339 (Pubitemid 26374499)
20. Borelli C, Kaudewitz P. Xanthelasma palpebrarum: treatment with the erbium: YAG laser. Lasers Surg Med 2001;29:260-264
21. Clarke R, Frost C, Collins R, Appleby P, Peto R. Dietary lipids and blood cholesterol: Quantitative meta-analysis of metabolic ward studies. Br Med J 1997;314,:112-117
22. Tang JL, Armitage JM, Lancaster T, Silagy CA, Fowler GH, Neil HA. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. Br Med J 1998;18;316:1213-1220
23. Mensink RP, Katan MB. Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials. Arterioscler Thromb 1992;12:911-919
24. Gardner CD, Kraemer HC. Monounsaturated versus polyunsaturated dietary fat and serum lipids. A meta-analysis. Arterioscler Thromb Vasc Biol 1995;15:1917-1927
25. Hooper L. UK Heart Health and Thoracic Dietitians Interest Group (Specialist interest group of the British Dietetic Association). Dietetic guidelines: Diet in secondary prevention of cardiovascular disease. J Hum Nutr Diet 2001;14:297-305.
26. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterollowering effects of dietary fiber: A meta-analysis. Am J Clin Nutr 1999;69:30-42.
27. Olson BH, Anderson SM, Becker MP, Anderson JW, Hunninghake DB, Jenkins DJ, et al. Psyllium-enriched cereals lower blood total cholesterol and LDL cholesterol, but not HDL cholesterol, in hypercholesterolemic adults: results of a metaanalysis. J Nutr 1997;127:1973-1980
28. Ripsin CM, Keenan JM, Jacobs DR Jr, Elmer PJ, Welch RR, Van Horn L, et al. Oat products and lipid lowering. A meta-analysis. JAMA 1992;24;267:3317-3325
29. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 1995;333:276-282
30. Alder R, Lookinland S, Berry JA, Williams M. A systematic review of the effectiveness of garlic as an anti-hyperlipidemic agent. J Am Acad Nurse Pract 2003;15:120-129
31. Endo A, Kuroda M and Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett 1976;72:323-326
32. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992;33:1569-1582
33. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretative history of the cholesterol controversy, part V: The discovery of the statins and the end of the controversy. J Lipid Res 2006;47:1339-1351
34. Charlton-Menys V, Durrington PN. Human cholesterol metabolism and therapeutic molecules. Exp Physiol. 2008;93:27-42.
35. Bhatnagar D, Durrington PN, Kumar S,Mackness MI, Dean JD, Boulton AJM. Effect of treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM. Diabetes 1995;44:460-465
36. Caslake MJ, Stewart G, Day SP, Daly E, McTaggart F, Chapman MJ, et al. Phenotype-dependent and -independent action of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. Atherosclerosis 2003;171:245-253
37. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998;81:66B-69B.
38. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
39. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. BMJ 2003;326:1423-1427
40. Brown MS, Goldstein JL. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997;89:331-340
41. Roitelman J, Masson D, Avner R, Ammon-Zufferey C, Perez A, Guyon-Gellin Y, et al. Apomine, a novel hypocholesterolemic agent, accelerates degradation of 3-hydroxy-3-methylglutarylcoenzyme A reductase and stimulates low density lipoprotein receptor activity. J Biol Chem. 2004;279:6465-6473
42. Fellstrom B. Impact and management of hyperlipidemia posttransplantation. Transplantation 2000;70:SS51-57.
43. Schwarz M, Lund EG, Russell DW. Two 7 α-hydroxylase enzymes in bile acid biosynthesis. Curr Opin Lipidol 1998;9:113-118
44. Shepherd J. Mechanism of action of bile acid sequestrants and other lipid-lowering drugs. Cardiology 1989;76:65-71.
45. Steinmetz KL, Schonder KS. Colesevelam: Potential uses for the newest bile resin. Cardiovasc Drug Rev 2005;23:15-30.
46. Bays HE, Davidson M, Jones MR, Abby SL. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and highsensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 2006;97:1198-1205.
47. LaRosa J. Review of clinical studies of bile acid sequestrants for lowering plasma lipid levels. Cardiology 1989;76:55-64.
48. Jacobson TA, Armani A, McKenney JM, Guyton JR. Safety considerations with gastrointestinally active lipid-lowering drugs. Am J Cardiol 2007;99:47C-55C
49. Crouse JR 3rd. Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. Am J Med 1987;83:243-248
50. Lorenzen A, Stannek C, Burmeister A, Kalvinsh I, Schwabe U. G protein-coupled receptor for nicotinic acid in mouse macrophages. Biochem Pharmacol 2002;64:645-648
51. Carlson LA, Orö L. Effect of treatment with nicotinic acid for one month on serum lipids in patients with different types of hyperlipidaemia. Atherosclerosis 1973;18:1-9.
52. Carlson LA. Nicotinic acid: The broad-spectrum lipid drug. A 50th anniversary review. J Intern Med. 2005;258:94-114.
53. Drexel H. Nicotinic acid in the treatment of hyperlipidaemia. Fundam Clin Pharmacol. 2007;21:5-6.
54. Carlson LA. Niaspan, the prolonged-release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug. Int J Clin Pract 2004;58:706-713
55. McCormack PL, Keating GM. Prolonged-release nicotinic acid: A review of its use in the treatment of dyslipidaemia. Drugs 2005;65:2719-2740
56. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000;405:421-424
57. Guay DR. Update on fenofibrate. Cardiovasc Drug Rev 2002;20:281-302.
58. Staels B, Auwerx J. Regulation of apo A-I gene expression by fibrates. Atherosclerosis, 1998;137:S19-S23.
59. Insua A, Massari F, Moncalvo JJR, Zanchetta JR, Insua AM. Fenofibrate or gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia. Endo Prac 2002;8:96-101.
60. Nityanand S, Kapoor NK. Cholesterol lowering activity of the various fractions of guggul. Indian J Exp Biol. 1973;11:395-398.
61. Chiang, J. Y. L.: Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms. J. Hepatol. 2004, 40, 539-551.
62. Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, et al. A natural product that lowers cholesterol as an antagonist ligand for the FXR. Science. 2002;296:1703-1706.
63. Deng R. Therapeutic Effects of Guggul and Its Constituent Guggulsterone: Cardiovascular Benefits. Cardiovasc Drug Rev. 2007;25:375-390
64. Szapary PO, Wolfe ML, Bloedon LT, Cucchiara AJ, DerMarderosian AH, Cirigliano MD, et al. Guggulipid for the treatment of hypercholesterolemia: A randomized controlled trial. JAMA. 2003;290:765-772
65. Ulbricht C, Basch E, Szapary P, Hammerness P, Axentsev S, Boon H, et al. Natural Standard Research Collaboration. Guggul for hyperlipidemia: A review by the Natural Standard Research Collaboration. Complement Ther Med. 2005;13:279-290
66. Sullivan DR. Recent trends in lipid management: raising the bar and shifting the goalposts? Intern Med J 2003;33:95-102.
67. Lilly SM, Rader DJ. New targets and emerging therapies for reducing LDL cholesterol. Curr Opin Lipidol 2007;18:650-655
68. Burnett D.A, Caplan M.A, Davis H.R Jr, Burrier RE, Clader JW. 2-Azetidinones as inhibitors of cholesterol absorption. J. Med. Chem 1994;37:1733-1736
69. Rau O, Zettl H, Popescu L, Steinhilber D, Schubert-Zsilavecz M. The Treatment of Dyslipidemia-What's Left in the Pipeline? ChemMedChem 2007;3206-3221
70. Gagné C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, et al. Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1084-1091
71. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1092-1097
72. Charlton-Menys V, Durrington PN. Squalene synthase inhibitors: Clinical pharmacology and cholesterol-lowering potential. Drugs 2007;67:11-16
73. The Expert Panel. Report of the National Cholesterol Educational Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988;148:36-69.
74. Summary of the second report of the National Cholesterol Educational Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 1993;269:3015-3023.